ADXS Advaxis Inc
Advaxis Inc focuses on discovery, development, and commercialization of proprietary Lm (Listeria monocytogenes)-LLO (Listeriolysin O) cancer immunotherapies.
$0.57
As of 04/13/2021 IEX book CBOE book
Security Information
Category1:
US EquityCategory2:
Common stocksCategory3:
Micro cap
GICS sector: Health Care
Industry: Biotechnology
Index country: USA
Country of incorporation: USA
IPO date: 07/28/2005
Outstanding shares: 120,382,668
Average volume: 3,784,725
Market cap: $68,618,121
Current dividend yield: 0.00%
All SEC filings:
SEC Edgar Online
Quarterly filings:
10-Q
Annual filings:
10-K
CUSIP: 007624307
ISIN: US0076243072
Sedol: BJK10R2
Valuation (See tab for details)
PE ratio: -6.66
PB ratio: 0.22
PS ratio: 36.79
Return on equity: -60.12%
Net income %: -1,211.21%